GLP-1 receptor agonists × glycemic control

Observational studyDiabetes, obesity & metabolism2020

Semaglutide once weekly in people with type 2 diabetes: Real-world analysis of the Canadian LMC diabetes registry (SPARE study).

Ruth E Brown et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 937 people · 2020

No range given

Reported higher glycemic control, no range given

+0.70mmol/mol

As reported

difference 0.7 mmol/mol, no interval

One number in the abstract

the abstract, start to end

difference - 0.24 ± 0.06%, 2.6 ± 0.7 mmol/mol; P < 0.001).

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Glycemic control
0.7
GLP-1 receptor agonistsGlycemic control
1 / 3

27 papers cite it

2020
2021
2022
2023
2024
2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 32538541